PF-Atlas › Clinical Trials › NCT03843892
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
OFEV · Not specified
Registry ID
NCT03843892
Phase
Not specified
Status
Approved For Marketing
Drug / intervention
OFEV
Sponsor
Boehringer Ingelheim
Locations
6
About this trial
This Expanded Access Program is intended to facilitate the availability of OFEV to patients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) with a progressive clinical course despite Standard of Care treatment and for whom no satisfactory authorised alternative therapy exists or who cannot enter a clinical trial.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03843892 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.